Difference between revisions of "Periampullary adenocarcinoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site" to "<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site-->") |
Warner-admin (talk | contribs) m (Text replacement - "</big>" to "") |
||
(51 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | < | + | <span id="BackToTop"></span> |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | < | + | [[#top|Back to Top]] |
− | + | </div> | |
− | + | {{#lst:Editorial board transclusions|giei}} | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | | | ||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
+ | ''Are you looking for a regimen, but can't find it here? For placebo or observational studies in this condition, please visit [[Periampullary adenocarcinoma - null regimens|this page]]. If you still can't find it, please let us know so we can add it!'' <br> | ||
+ | Note: there is some overlap, especially in the earlier literature, between treatment regimens for periampullary adenocarcinoma and those for '''[[pancreatic cancer|pancreatic adenocarcinoma]]''', '''[[cholangiocarcinoma]]''', and '''[[gallbladder cancer]]'''; please see those pages for additional regimens. | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
− | |||
=Guidelines= | =Guidelines= | ||
− | ==[ | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
− | *'''2016:''' [ | + | ==[https://www.esmo.org/ ESMO]== |
− | + | *'''2016:''' [https://doi.org/10.1093/annonc/mdw324 Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://pubmed.ncbi.nlm.nih.gov/27664259/ PubMed] | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | == | + | ==NCCN== |
− | + | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1511 NCCN Guidelines - Ampullary Adenocarcinoma] | |
+ | **'''2023:''' Chiorean et al. [https://doi.org/10.6004/Jnccn.2023.0034 Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.] [https://pubmed.ncbi.nlm.nih.gov/37433437/ PubMed] | ||
[[Category:Periampullary adenocarcinoma regimens]] | [[Category:Periampullary adenocarcinoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
− | [[Category: | + | [[Category:Biliary tract cancers]] |
Latest revision as of 00:28, 4 July 2024
Section editor | |
---|---|
Eric I. Marks, MD Boston University Boston, MA, USA |
0 regimens on this page
0 variants on this page
|
Are you looking for a regimen, but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
Note: there is some overlap, especially in the earlier literature, between treatment regimens for periampullary adenocarcinoma and those for pancreatic adenocarcinoma, cholangiocarcinoma, and gallbladder cancer; please see those pages for additional regimens.
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
- 2016: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed